Although presurgical treatment with high doses of SRLs was associated with a 2.2-fold greater chance of surgical remission in GH-pituitary macroadenomas, this benefit was not related with changes in tumor consistency induced by the presurgical treatment. Here, GH1 is linked to neoplasm.